SomnoMed (SomnoMed) Common Stock : $59.47 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is SomnoMed Common Stock?

SomnoMed's quarterly common stock declined from Dec. 2022 ($50.12 Mil) to Jun. 2023 ($49.85 Mil) but then increased from Jun. 2023 ($49.85 Mil) to Dec. 2023 ($59.47 Mil).

SomnoMed's annual common stock declined from Jun. 2021 ($56.77 Mil) to Jun. 2022 ($52.19 Mil) and declined from Jun. 2022 ($52.19 Mil) to Jun. 2023 ($49.85 Mil).

SomnoMed Common Stock Historical Data

The historical data trend for SomnoMed's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SomnoMed Common Stock Chart

SomnoMed Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Common Stock

Get a 7-Day Free Trial

40.06

51.03

56.77

52.19

49.85

SomnoMed Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Common Stock	Get a 7-Day Free Trial															53.13	52.19	50.12	49.85	59.47

SomnoMed Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

SomnoMed (SomnoMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SomnoMed Ltd (OTCPK:SOMNF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

RJV:Germany SOM:Australia

Address

20 Clarke Street, Level 3, Crows Nest, Sydney, NSW, AUS, 2065

Website

https://www.somnomed.com/au

SomnoMed Ltd produces and sells oral treatment of sleep-related disorder devices. It manufactures and designs premium oral appliances for the treatment of sleep-disordered breathing relieving conditions. Its products include SomnoDent, Som Tabs, Som Morning Repositioner and others. Its geographical segments include North America, Europe, and Asia-Pacific. Business operations consist of the production and sale of products treating sleep-disordered breathing, which is the only reportable segment. Substantial revenue is realized from the European region.

SomnoMed (SomnoMed) Headlines

From GuruFocus

SomnoMed posts record Q4 and delivers on FY22 revenue guidance

By PRNewswire PRNewswire • 07-26-2022

SomnoMed's North America Q1 revenue growth leads the way

By PRNewswire PRNewswire • 10-28-2022